Merck formally announces Galvis as new head in Brazil

Germany-based pharma major Merck has officially appointed Pedro Galvis as the new president of its Brazil subsidiary. He will take office on May 1 after current head Guilherme Maradei becomes oncology marketing director in the U.S. As GBI reported, earlier this month the company announced that José-Arnaud de Carvalho Coelho would direct the firm’s operations in Mexico to fill in for Galvis.

After starting his career in Merck Colombia, Galvis has served in a number of leadership positions including regional director of the generics division for Latin America, as well as director of the cardiometabolism and general medicines business unit. Working under Maya Martínez-Davis, biopharma president in Latin America, he will now have the task of maintaining the company’s sustainable growth in the country while overseeing launches planned in the areas of oncology, neurology, immunology, and general medicine.


Related news
Chengdu-based biotech HitGen Ltd, announced that its drug discovery partnership with U.S.-based Merck, Sharp & Dohme (MSD) has achieved a milestone with the identification of several viable candidates meeting pre-defined criteria.
GBI analysis reveals that Ecuador's National Agency for Health Regulation, Control and Surveillance (ARCSA) last week granted marketing approval to Germany-based giant Merck’s immunosuppressant Mavenclad (cladribine).
The China Primary Health Care Foundation (CPHCF)’s Tumor Immunotherapy Patient Assistance Program (PAP) office announced the initiation of a patient assistance project in relation to use of U.S.-based giant Merck, Sharp & Dohme’s Keytruda (pembrolizumab) in treating lung cancer.
  • 1554952639218
  • China
  • Drug
Germany-based pharmaceutical giant Merck KGaA has appointed José-Arnaud de Carvalho Coelho as the general director of the firm’s Mexico subsidiary and Healthcare Division, starting this month​.
  • 1554888320349
  • Brazil,Mexico,Argentina
  • Company
The director of the U.S. FDA’s Oncology Center of Excellence, Richard Pazdur, has issued a welcome to Chinese companies to bring low-cost programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors to the U.S. market.
Recent news
A Sino-US team of researchers have reported developing a new improved chimeric antigen receptor (CAR) T cell therapy, according to a study published in Nature Medicine.
  • 1556168634038
  • China
  • R&D
China-based Viva Biotech Holdings (1873.HK) announced an initial public offering (IPO) of 345,000,000 shares with price ranging from HKD 3.42 to HKD 4.41 per share.
Switzerland-based ADC Therapeutics and the China-based Adagene announced a discovery partnership and licensing deal focused on the development of next-generation masked antibody drug conjugates (ADCs).
U.S.-based Boston Children's Hospital (BCH) and Sino-US high-end clinics operator and healthcare service provider MORE Health Inc., announced a strategic partnership that will allow Chinese patients to access BCH's physicians for diagnosis and treatment.
China’s National Medical Products Administration (NMPA) released the medical devices awarded market approval during March 2019.
The Brazilian Society of Diabetes (SBD) this week will discuss the benefits of Technosphere insulin, a fast-acting inhalable diabetes treatment.
Brazil's Industry Syndicate of Pharmaceutical Products (SINDUSFARMA) this month presented the results of a study on the viability of the drug inverse logistics system, commissioned to Netherlands-based consulting firm KPMG.
Analytics Snapshot

Understand market developments and maintain your competitive advantage.